ArticleTranslational cancer research2021
Predictors and survival of primary clear cell carcinoma of liver: a population-based study of an uncommon primary liver tumor.
Article in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multimodal imaging findings of primary liver clear cell carcinoma: a case presentation.Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinicopathological features and prognostic factors of primary clear cell carcinoma of the liver (PCCCL) remain unknown for the rarity. We aimed to determine the clinical and therapeutic characteristics of PCCCL and the effects of these factors on the prognosis.
methodsPatients were selected from the Surveillance, Epidemiology, and End Results (SEER) database. Data were analyzed with the Kaplan-Meier, Cox proportional hazards regression analyses and the multivariable competing risk model.
resultsWe included 223 PCCCL patients and the majority of them had an age under 75 years (82.5%). Most patients were white people (63.2%). The patients diagnosed at localized stage (63.7%), T1 (49.8%), N0 (96.0%), M0 (87.4%) and American Joint Committee on Cancer (AJCC) I (44.4%) made up the majority of the population. More PCCCL tumors had a size beneath 4 cm (74.9%) and no vascular invasion (63.2%). The 3-, 5-, and 10-year overall survival (OS) probabilities and disease-specific survival (DSS) rates were 35.8%, 24.3%, 14.4%, and 41.6%, 29.4%, 22.2%, respectively. The patients with tumor ≥1 cm [OS, hazard ratio (HR) =1.822; DSS, HR =1.959] had a higher risk of death than those patients with tumor <1 cm. Among surgical means, hepatectomy (OS, HR =0.070; DSS, HR =0.050) and total hepatectomy plus transplant (OS, HR =0.074; DSS, HR =0.065) were more beneficial to PCCCL.
conclusionsPCCCL patients were inclined to be young, white people-prevalent, localized and early. PCCCL tend to had a slow growth and be weakly aggressive. However, comparing with previous reports, we found that PCCCL had a relatively poor outcome. Tumor size and surgery were the independent prognostic factors for OS and DSS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.